Analysts have been eager to weigh in on the Healthcare sector with new ratings on Zymeworks (ZYME – Research Report), Cooper Co (COO – Research Report) and MannKind (MNKD – Research Report).
Cooper Co (COO)
In a report issued on September 7, Jeff Johnson from Robert W. Baird maintained a Hold rating on Cooper Co, with a price target of $345.00. The company’s shares closed last Friday at $314.70.
According to TipRanks.com, Johnson is a 5-star analyst with an average return of
Cooper Co has an analyst consensus of Moderate Buy, with a price target consensus of $347.50, representing a 12.6% upside. In a report issued on August 29, KeyBanc also downgraded the stock to Hold.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ZYME:
- Analysts’ Opinions Are Mixed on These Technology Stocks: Phreesia (PHR), AeroVironment (AVAV) and Coupa Software (COUP)
- Robert W. Baird Sticks to Their Hold Rating for Fastenal Company (FAST)
- Robert W. Baird Releases a Buy Rating on TaskUs (TASK)
- Robert W. Baird Sticks to Its Buy Rating for Asana (ASAN)
- Robert W. Baird Reaffirms Their Buy Rating on Paymentus Holdings (PAY)
